Is NfL the New 'N' in A/T/N Classification of Alzheimer’s?
People with a lot of neurofilament light protein are more likely to develop mild cognitive impairment in the next four years.
NEWS
Amyloid PET Aids Diagnosis. But Could CSF Do Just as Well?
Large IDEAS data set establishes that PET scans are valuable in clinical practice. Other studies suggest CSF biomarker ratios perform nearly as well.
It’s Official: Tau PET Sees Tangles, and Staging Tangles Predicts Decline
Scientists at CTAD were excited about postmortem validation of tau scans and new, more sensitive tracers. Others are exploring practical applications for live imaging of tau pathology.
Toxic Stew of Aβ Dimers Hides Out in Human Plaques
Brains of Alzheimer’s patients contain Aβ dimers consisting of monomers Aβ37 to Aβ42 and held together by covalent bonds.
Blood Tests for Amyloid Step Out at CTAD
With plasma tests performing in AIBL staging, scientists are sharing data across platforms and cohorts, and tackling standardization to avoid time lost to irreproducibility.
Can Clinical Trials and Longitudinal Studies Crack Rare Tauopathies?
International conference gives scientists hope for understanding and treating PSP and CBD.
International Symposium Puts PSP/CBD on the Map
Researchers gain traction in the study of these rare tau disorders, which are sometimes confused with Alzheimer’s disease.
NfL in Blood Foretells Poor Brain Health After the Heart Stops
Neurofilament light protein in the serum registers the degree of axonal damage after cardiac arrest, and may help doctors predict long-term consequences for the brain.
Virtual Exhibit Hall
Alzforum encourages users to visit the Virtual Exhibit Hall, where companies showcase their newest initiatives, products, and services. We welcome Dash Genomics, Inc. and Abcam, which join our other exhibitors — Biogen, BioLegend, NanoString Technologies, Inc., and the Jackson Laboratory.
SPOTLIGHT
International Symposium Puts PSP/CBD on the Map
Tufted astrocytes? Astrocytic plaques? These tau pathologies mark progressive supranuclear palsy and corticobasal degeneration, respectively. The science of these difficult-to-diagnose diseases may finally be taking off. Read Tom Fagan’s coverage of the first PSP & CBD International Research Symposium held in London. Learn how genetics are yielding clues toward pathways, and natural history cohorts and therapeutic trials are getting underway.
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- New Items: 5
- Total Items: 228
-
Jobs
- New Items: 4
- Total Items: 94
-
Conference Calendar
- New Items: 7
- Total Items: 52
- Member Directory
Latest Comments